oxybutynin has been researched along with Atrial Fibrillation in 7 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The incidence of adverse events did not differ between the groups." | 6.90 | Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). ( Akita, Y; Ikeda, T; Yamashita, T, 2019) |
| "We examined the efficacy of TDPB for paroxysmal atrial fibrillation (PAF) after open heart surgery." | 5.46 | [Efficacy of Transdermal Patch of Bisoprolol for Paroxysmal Atrial Fibrillation after Open Heart Surgery]. ( Enomoto, S; Hamuro, M; Kawatou, M; Yamada, T; Yamamoto, K, 2017) |
| "The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min." | 5.43 | Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. ( Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K, 2016) |
| "The transdermal formulation of bisoprolol may be useful for the early introduction of β-blockers in patients admitted with cardiac symptoms associated with myocardial ischemia or heart failure." | 4.02 | An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms. ( Horiuchi, N; Kobayashi, T; Kobayashi, Y; Nakamura, S; Nakanishi, H; Naruhashi, K; Nozaki, A; Okugawa, H, 2021) |
| " The incidence of adverse events did not differ between the groups." | 2.90 | Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study). ( Akita, Y; Ikeda, T; Yamashita, T, 2019) |
| "We examined the efficacy of TDPB for paroxysmal atrial fibrillation (PAF) after open heart surgery." | 1.46 | [Efficacy of Transdermal Patch of Bisoprolol for Paroxysmal Atrial Fibrillation after Open Heart Surgery]. ( Enomoto, S; Hamuro, M; Kawatou, M; Yamada, T; Yamamoto, K, 2017) |
| "The bisoprolol patch was introduced 88 h after the start of landiolol administration, when the rate was approximately 3 μg/kg/min." | 1.43 | Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. ( Doi, K; Hiruma, T; Inokuchi, R; Nakajima, S; Nakamura, K; Tokunaga, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Nozaki, A | 1 |
| Kobayashi, T | 1 |
| Naruhashi, K | 1 |
| Okugawa, H | 1 |
| Horiuchi, N | 1 |
| Nakanishi, H | 1 |
| Kobayashi, Y | 1 |
| Nakamura, S | 1 |
| Iwano, T | 1 |
| Toda, H | 1 |
| Nakamura, K | 2 |
| Shimizu, K | 1 |
| Ejiri, K | 1 |
| Naito, Y | 1 |
| Mori, H | 1 |
| Masuda, T | 1 |
| Miyoshi, T | 1 |
| Yoshida, M | 1 |
| Hikasa, Y | 1 |
| Morimatsu, H | 1 |
| Ito, H | 1 |
| Yamamoto, K | 1 |
| Yamada, T | 1 |
| Hamuro, M | 1 |
| Kawatou, M | 1 |
| Enomoto, S | 1 |
| Yamashita, T | 1 |
| Ikeda, T | 1 |
| Akita, Y | 1 |
| Okamura, H | 1 |
| Arakawa, M | 1 |
| Miyagawa, A | 1 |
| Adachi, H | 1 |
| Lee, J | 1 |
| Burke, DT | 1 |
| Inokuchi, R | 1 |
| Hiruma, T | 1 |
| Tokunaga, K | 1 |
| Doi, K | 1 |
| Nakajima, S | 1 |
2 trials available for oxybutynin and Atrial Fibrillation
| Article | Year |
|---|---|
Preventative effects of bisoprolol transdermal patches on postoperative atrial fibrillation in high-risk patients undergoing non-cardiac surgery: A subanalysis of the MAMACARI study.
Topics: Aged; Atrial Fibrillation; Bisoprolol; Humans; Postoperative Complications; Risk Factors; Stroke; Tr | 2021 |
Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO-AF study).
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Asian People; Atrial Fibrillatio | 2019 |
5 other studies available for oxybutynin and Atrial Fibrillation
| Article | Year |
|---|---|
An attempt at administering a transdermal formulation of bisoprolol in patients with acute cardiac symptoms.
Topics: Acute Coronary Syndrome; Acute Disease; Administration, Cutaneous; Adrenergic beta-1 Receptor Antago | 2021 |
[Efficacy of Transdermal Patch of Bisoprolol for Paroxysmal Atrial Fibrillation after Open Heart Surgery].
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atrial Fibrillation; Bisoprolol; Cardiac Surgical | 2017 |
Incidence of postoperative atrial fibrillation in transdermal β-blocker patch users is lower than that in oral β-blocker users after cardiac and/or thoracic aortic surgery.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Cardiac Surgical Proce | 2019 |
Lower gastrointestinal bleeding associated with diclofenac topical patch in a patient with colonic mass and on antiplatelet therapy for atrial fibrillation.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Clopidogrel; Colonic Neoplasms; | 2014 |
Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; B | 2016 |